ArticleCureus2025
Beginning of ABO-Incompatible Transplants in Pakistan: A Single-Centre Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The burden of end-stage renal disease (ESRD) is ever-increasing in Pakistan. Among the treatment options available, kidney transplantation remains the most effective treatment for ESRD, offering improved quality of life and survival benefits over dialysis. ABO blood group incompatibility has traditionally been viewed as a barrier to transplantation. However, we have started ABO-incompatible (ABOi) renal transplant in Pakistan since 2023 with good clinical outcomes. Objectives This study aims to document the initiation of ABOi renal transplants in Pakistan, while evaluating clinical outcomes, immunological responses, and long-term graft survival rates, with a focus on the development and further improvement of pre-transplant desensitisation regimens. Methods A retrospective study was conducted at our centre on ABOi renal transplants from February 2023 to March 2025. A total of 15 ABOi renal transplants were included. The desensitisation protocol developed included immunomodulation with rituximab, followed by low-dose immunosuppression and membrane plasma separation for preformed antibody depletion. Induction therapy was performed using anti-thymocyte globulin (ATG). Immunosuppression consisted of tacrolimus (0.1 mg/kg/day), mycophenolate mofetil or MMF (2000 mg/day), and prednisolone (1 mg/kg/day). All patients were given trimethoprim-sulfamethoxazole 160/800 on alternate days for six months as prophylaxis against Pneumocystis jirovecii pneumonia (PJP), valganciclovir 450 mg per day against cytomegalovirus (CMV) for three months, and fluconazole 50 mg per day for one month as antifungal prophylaxis. Results The highest antibody titers pre-transplant were 1/512 (IgG) and 1/256 (IgM). Five sessions of plasmapheresis were done for 13 (86.7%) patients, while two (13.3%) underwent immunoadsorption (IA). The cutoff of 1:4 was established to go ahead with the transplant. Overall graft survival was 86.7%. Three (20.0%) patients developed cellular rejection, which was successfully treated. One (6.7%) patient died with a functioning graft due to secondary complications. The main complications encountered were development of lymphocele, urinary leakage, lower respiratory tract infection, and urinary tract infection. Conclusion We conclude that the ABOi renal transplants in Pakistan show favourable results. Further adoption of this method can expand the donor pool for patients with ESRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.